Weight Gain and Glucose Dysregulation with Second-Generation Antipsychotics and Antidepressants:
A Review for Primary Care Physicians Mehrul Hasnain, MD; W. Victor R. Vieweg, MD; Bruce Hollett, MD DOI: 10.3810/pgm.2012.07.2577 Abstract: Second-generation antipsychotics (SGAPs) and second-generation antidepressants (SGADs) have multiple US Food and Drug Administration–approved indications and are frequently prescribed by primary care physicians. We review the relative potential of these drugs to cause weight gain and glucose dysregulation, and offer clinical guidance to minimize and manage this risk. Among SGAPs, clozapine and olanzapine have a high risk for causing weight gain and glucose dysregulatio...
Source: Postgraduate Medicine Online - August 8, 2012 Category: Internal Medicine Authors: admin Source Type: research
Time to all-cause treatment discontinuation of olanzapine compared to other antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis
Conclusion: Using a global measure of medication effectiveness (time to all-cause medication discontinuation), olanzapine appears to be more effective – in both RCTs and observational studies – than most SGAs and FGAs, except for clozapine. (Source: European Neuropsychopharmacology)
Source: European Neuropsychopharmacology - May 28, 2012 Category: Psychiatry & Psychology Authors: Karla Soares-Weiser, Laura Béchard-Evans, Anthony Howard Lawson, John Davis, Haya Ascher-Svanum Tags: Clinical Science Source Type: research